Neuroblastoma: Effect of genetic factors on prognosis and treatment

Cancer

Volumn 70, Issue 4 S, 1992, Pages 1685-1694

  Brodeur, Garrett M ^a,f,g   Azar, Christopher ^a,g   Brother, Michele ^a,g   Hiemstra, Jill ^a,g   Kaufman, Bruce ^a,g   Marshall, Helen ^a,g   Moley, Jeffrey ^a,g   Nakagawara, Akira ^a,g   Saylors, Robert ^a,g   Scavarda, Nancy ^a,g   Schneider, Sandra ^a,g   Wasson, Jonathon ^a,g   White, Peter ^a,g   Seeger, Robert ^b,e   Look, Thomas ^c,f   Castleberry, Robert ^d,f  

^a Departments of Pediatrics   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e Children's Cancer Study Group   (United States)

^f Pediatric Oncology Group   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

deletion of chromosome Ip; loss of heterozygosity (LOH); molecular genetics; neuroblastoma; NGF receptor (NGFR); N myc amplification; oncogenes; prognostic factors; suppressor genes; tumor cell DNA content

Indexed keywords

DNA; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR; RNA;

CANCER SUSCEPTIBILITY; CHROMOSOME; CHROMOSOME DELETION; CONFERENCE PAPER; CYTOGENETICS; DNA CONTENT; DNA PROBE; FLOW CYTOMETRY; GENE AMPLIFICATION; HEREDITY; HETEROZYGOSITY; HUMAN; IMMUNOBLOTTING; KARYOTYPE; MOLECULAR GENETICS; MUTATION; NEUROBLASTOMA; ONCOGENE; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR AFFINITY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

CELL LINE; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOME DISORDERS; GENE AMPLIFICATION; GENES, MYC; GENETIC TECHNIQUES; HUMAN; INFANT; NEUROBLASTOMA; PLOIDIES; PROGNOSIS; RECEPTORS, CELL SURFACE; RECEPTORS, NERVE GROWTH FACTOR; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026726144     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19920915)70:4+<1685::AID-CNCR2820701607>3.0.CO;2-H     Document Type: Article

References (80)

1. Molecular biology and genetics of human neuroblastoma
2. Neuroblastoma: clinical applications of molecular parameters
3. Molecular biology and genetics of human neuroblastoma
4. Chromosomal aberrations in human neuroblastomas
5. Human neuroblastoma cytogenetics: search for significance of homogeneously staining regions and double minute chromosomes
6. Cytogenetic features of human neuroblastomas and cell lines
7. Human neuroblastomas and abnormalities of chromosome 1 and 17
8. Molecular analysis and clinical significance of N‐myc amplification and chromosome 1 abnormalities in human neuroblastomas
9. Tumour karyotype may be important in the prognosis of human neuroblastoma
10. Chromosome findings and prognosis in neuroblastoma
11. Different karyotypic patterns in early and advanced stage neuroblastomas
12. Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma
13. Chromosome findings and prognosis in 15 patients with neuroblastoma found by VMA mass screening
14. Loss of heterozygosity for chromosome Ip in human neuroblastomas: correlation with N‐myc amplification
15. Neuroblastoma consensus deletion maps to 1p 36.1‐2
16. Frequent loss of heterozygosity on chromosome 14q in neuroblastoma
17. Relationship between homogeneously staining regions and double minute chromosomes in human neuroblastoma cell lines
18. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour
19. Transposition and amplification of oncogene‐related sequences in human neuroblastomas
20. Specific DNA sequence amplification in human neuroblastoma cells
21. Chromosome localization in normal human cells and neuroblastomas of a gene related to c‐myc
22. Gene amplification in human neuroblastomas: basic mechanisms and clinical implications
23. Excision of N‐myc from chromosome 2 in human neuroblastoma cells containing amplified N‐myc sequences
24. Amplification units containing human N‐myc and c‐myc genes
25. Characterization of N‐myc amplification units in human neuroblastoma cells
26. Differential amplification, assembly and relocation of multiple DNA sequences in human neuroblastomas and neuroblastoma cell lines
27. Amplification and rearrangement of DNA sequences from the chromosomal region 2p24 in human neuroblastomas
28. Amplified N‐myc in human neuroblastoma cells is often arranged as clustered tandem repeats of differently recombined DNA
29. Yeast artificial chromosome (YAC) vector cloning of the MYCN amplified domain in human neuroblastomas
30. Amplification of N‐myc in untreated human neuroblastomas correlates with advanced disease stage
31. A proposed staging for children with neuroblastoma: Children's Cancer Study Group
32. Association of multiple copies of the N‐myc oncogene with rapid progression of neuroblastomas
33. Clinical implications of oncogene activation in human neuroblastomas
34. Analysis of N‐myc amplification in relation to disease stage and histologic types in human neuroblastomas
35. Amplification of N‐myc oncogene in stage II and IVS neuroblastomas may be a prognostic indicator
36. Amplification and expression of the N‐myc gene in neuroblastoma
37. Clinical relevance of tumor cell ploidy and N‐myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study
38. Analysis of DNA ploidy and proliferative activity in relation to histology and N‐myc amplification in neuroblastoma
39. A comparative analysis of nuclear DNA content and N‐myc gene amplification in neuroblastoma
40. Combined analysis of DNA ploidy index and N‐myc genomic content in neuroblastoma
41. Consistent N‐myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients
42. Detection of N‐myc expression in human neuroblastoma by in situ hybridization and blot analysis: relationship to clinical outcome
43. Expression of N‐myc by neuroblastomas with one or multiple copies of the oncogene
44. N‐myc oncogene RNA expression in neuroblastoma
45. Myc gene amplification and expression in primary human neuroblastoma
46. Activated expression of the N‐myc gene in human neuroblastomas and related tumors
47. Differential protooncogene expression characterizes histopathologically indistinguishable tumors of the peripheral nervous system
48. Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1
49. Isolation and preliminary characterization of the transforming gene of a human neuroblastoma cell line
50. Structure and activation of the human N‐ras gene
51. Incidence of ras gene mutations in neuroblastoma
52. Activated N‐ras oncogenes in human neuroblastoma
53. Low frequency of ras gene mutations in neuroblastomas, pheochromocytomas and medullary thyroid cancers
54. Expression of Ha‐ras oncogene products in human neuroblastomas and the significant correlation with a patient's prognosis
55. Cellular DNA content as predictor of response to chemotherapy in infants with unresectable neuroblastoma
56. Flow cytometric DNA analysis of neuroblastoma: correlation with histology and clinical outcome
57. Flow cytometric DNA analysis of neuroblastoma and ganglio‐neuroma: a 10‐year retrospective study
58. Prognostic factors in neuroblastoma: clinical, histopathologic, immuno‐histochemical features and DNA ploidy in relation to prognosis
59. Flow cytometric analysis of DNA content in children with neuroblastoma
60. Physiology of nerve growth factor
61. A single Mr = 103,000 1251‐b‐nerve growth factor‐affinity‐labeled species represents both the low and high affinity forms of the nerve growth factor receptor
62. Indication of neurite outgrowth in the IMR‐32 human neuroblastoma cell line by nerve growth factor
63. Nerve growth factor effects and receptors in cultured human neuroblastoma cell lines
64. NGF‐induced differentiation of human neuroblastoma and neuroepithelioma cell lines
65. Multiple defects of the nerve growth factor receptor in human neuroblastomas
66. Analysis of nerve growth factor receptor expression in human neuroblastoma and neuroepithelioma cell lines
67. Nerve growth factor receptors on PC1 2 cells: evidence for two receptor classes with differing cytoskeletal association
68. Nerve growth factor rapidly induces c‐fos mRNA in PC12 rat pheochromocytoma cells
69. Nerve growth factor and epidermal growth factor induce rapid transient changes in proto‐oncogene transcription in PC12 cells
70. Super induction of c‐fos by nerve growth factor in the presence of peripherally active benzodiazepines
71. A nerve growth factor‐induced gene encodes a possible transcriptional regulatory factor
72. Nerve growth factor induces a gene homologous to the glucocorticoid receptor gene
73. Nerve growth factor and dibutyryl cyclic AMP induce neurite outgrowth in a clone derived from an NGF‐insensitive human neuroblastoma cell line
74. Decreased expression of N‐myc precedes retinoic acid‐induced morphological differentiation of human neuroblastoma
75. Neuroblastoma: inverse relationship between expression of N‐myc and NGF‐r
76. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma